BioCorRx (BICX) Gross Margin (2011 - 2026)

BioCorRx has disclosed Gross Margin across 16 years of filings, most recently posting 88.26% for Q1 2026.

• Gross Margin for Q1 2026 came in at 88.26%, down 1174.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 27.25% (down 7275.0% YoY), and the FY2024 annual result was 78.25%, up 1861.0% from the prior year.
• Gross Margin came in at 88.26% for Q1 2026 at BioCorRx, down from 100.0% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2024 to a low of 31.08% in Q4 2023.
• The 5-year median for Gross Margin is 85.62% (2026), against an average of 76.94%.
• Across the five-year window, Gross Margin sank 5846 bps in 2023 and soared 5284 bps in 2024, its largest moves.
• BioCorRx's Gross Margin stood at 89.53% in 2022, then slumped by 65 bps to 31.08% in 2023, then surged by 222 bps to 100.0% in 2024, then changed by 0 bps to 100.0% in 2025, then fell by 12 bps to 88.26% in 2026.
• The last three Gross Margin figures came in at 88.26% (Q1 2026), 100.0% (Q1 2025), and 100.0% (Q2 2024), per Business Quant data.